Cardiol Therapeutics’ ARCHER Phase II Study Results Published in ESC Heart Failure

Toronto, ON – February 10, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. The peer-reviewed article reports results from a randomized, double-blind, placebo-controlled trial evaluating CardiolRx™, Cardiol’s lead oral drug candidate, in 109 patients with acute myocarditis using advanced cardiac magnetic resonance (CMR) imaging measures of myocardial inflammation and remodelling. In the study, treatment with CardiolRx™ produced a significant reduction in left ventricular mass versus placebo (–9.2 g; p=0.0117), along with a decrease in left atrial remodelling, and favorable trends across multiple markers of myocardial inflammation. CardiolRx was also shown to be safe and well tolerated. Reduction in left ventricular mass is widely considered consistent with decreased myocardial edema and inflammatory burden in myocarditis and improved clinical outcomes. The biological signals observed in ARCHER are directly relevant to Cardiol’s ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis. Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, respectively, and are recognized to fall within the spectrum of inflammatory myopericardial syndrome, an umbrella term describing the potential myocarditis–pericarditis overlap: similar causes, anatomical contiguous structures, and mixed forms with possible reciprocal involvement, such as myopericarditis and perimyocarditis. “This publication marks an important moment in the broader dissemination of CardiolRx’s therapeutic potential,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “ARCHER provides additional compelling clinical evidence that CardiolRx impacts the underlying biology of inflammatory heart disease and reduces inflammation-driven structural damage in the heart, increasing our confidence in MAVERIC, which is focused on delivering meaningful outcomes for patients with recurrent pericarditis.” The full paper is available at: https://academic.oup.com/eschf/advance-article/doi/10.1093/eschf/xvaf034/8427108 About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population. The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year. For more information about Cardiol Therapeutics, please visit cardiolrx.com. Cautionary statement regarding forward-looking information: This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are “forward-looking information”. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx™, the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of the first-in-human clinical evaluation, and the Company’s belief that results from the ARCHER trial provide compelling clinical proof of concept for CardiolRx™, strengthen the scientific and clinical rationale for Cardiol’s lead Phase III program in recurrent pericarditis. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. For further information, please contact: [email protected] Press Releases Press Release Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionSeptember 10, 2026 Press Release Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 Press Release Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 46th Annual Growth ConferenceAugust 5, 2026 View all Join our newsletter Sign up to receive the latest news from Cardiol Therapeutics! By subscribing you agree to with our Privacy Policy Name(Required) First Last Email(Required) CAPTCHA Subscribe gform.initializeOnLoaded( function() {jQuery('#gform_ajax_frame_8').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_8');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_8').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_8').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_8').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_8').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_8').offset().top - mt); }, 50 );var current_page = jQuery('#gform_source_page_number_8').val();jQuery(document).trigger('gform_page_loaded', [8, current_page]);window['gf_submitting_8'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_8').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_8').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [8]);window['gf_submitting_8'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_8').text());}else{jQuery('#gform_8').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "current_page", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, current_page ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );} ); Company Company Management Team Board of Directors Scientific Advisory Board Our Advisors Collaborators Our Focus Pericarditis Myocarditis Heart Failure The Inflammasome Pipeline Clinical Trials CardiolRx™ CRD-38 Partnering Insights Blog Community Engagement Resources Investors Events & Presentations Press Releases Analyst Coverage Stock Information Filings & Financials Corporate Governance FAQ Contact Us .cls-1{fill:#fff;} 2026 Cardiol Therapeutics. All right reserved. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/cardiolrebuild/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} (function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/343442423.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000); var ajax_obj = {"ajax_url":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","nonce":"de3b463ba4"}; //# sourceURL=functions-js-extra wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var gform_i18n = {"datepicker":{"wdOffset":1,"helpTextShort":"Press F1 for help","helpText":"Press the arrow keys to navigate by day, PageUp and PageDown to navigate by month, Alt+PageUp and Alt+PageDown to navigate by year, or Escape to cancel.","openOnFocusHelpText":"Press Down arrow to browse the calendar, or Escape to close.","tooltipTxt":"Press Escape to cancel","disabledTxt":"Disabled","markedTxt":"Selected","prevTxt":"Previous","nextTxt":"Next","monthTxt":"Month","yearTxt":"Year","months":["January","February","March","April","May","June","July","August","September","October","November","December"],"days":[{"s":"S","l":"Sunday"},{"s":"M","l":"Monday"},{"s":"T","l":"Tuesday"},{"s":"W","l":"Wednesday"},{"s":"T","l":"Thursday"},{"s":"F","l":"Friday"},{"s":"S","l":"Saturday"}]}}; var gf_legacy_multi = []; var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","file_uploaded":"File uploaded","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled","error":"Error","message":"Message"},"vars":{"images_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/images"}}; var gf_global = {"gf_currency_config":{"name":"U.S. Dollar","symbol_left":"$","symbol_right":"","symbol_padding":"","thousand_separator":",","decimal_separator":".","decimals":2,"code":"USD"},"base_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms","number_formats":[],"version_hash":"bd2ea601f0155d066a4f3802a65e82de","countries":{"AF":"Afghanistan","AX":"\u00c5land Islands","AL":"Albania","DZ":"Algeria","AS":"American Samoa","AD":"Andorra","AO":"Angola","AI":"Anguilla","AQ":"Antarctica","AG":"Antigua and Barbuda","AR":"Argentina","AM":"Armenia","AW":"Aruba","AU":"Australia","AT":"Austria","AZ":"Azerbaijan","BS":"Bahamas","BH":"Bahrain","BD":"Bangladesh","BB":"Barbados","BY":"Belarus","BE":"Belgium","BZ":"Belize","BJ":"Benin","BM":"Bermuda","BT":"Bhutan","BO":"Bolivia","BQ":"Bonaire, Sint Eustatius and Saba","BA":"Bosnia and Herzegovina","BW":"Botswana","BV":"Bouvet Island","BR":"Brazil","IO":"British Indian Ocean Territory","BN":"Brunei Darussalam","BG":"Bulgaria","BF":"Burkina Faso","BI":"Burundi","CV":"Cabo Verde","KH":"Cambodia","CM":"Cameroon","CA":"Canada","KY":"Cayman Islands","CF":"Central African Republic","TD":"Chad","CL":"Chile","CN":"China","CX":"Christmas Island","CC":"Cocos Islands","CO":"Colombia","KM":"Comoros","CD":"Congo, Democratic Republic of the","CG":"Congo","CK":"Cook Islands","CR":"Costa Rica","CI":"C\u00f4te d'Ivoire","HR":"Croatia","CU":"Cuba","CW":"Cura\u00e7ao","CY":"Cyprus","CZ":"Czechia","DK":"Denmark","DJ":"Djibouti","DM":"Dominica","DO":"Dominican Republic","EC":"Ecuador","EG":"Egypt","SV":"El Salvador","GQ":"Equatorial Guinea","ER":"Eritrea","EE":"Estonia","SZ":"Eswatini","ET":"Ethiopia","FK":"Falkland Islands","FO":"Faroe Islands","FJ":"Fiji","FI":"Finland","FR":"France","GF":"French Guiana","PF":"French Polynesia","TF":"French Southern Territories","GA":"Gabon","GM":"Gambia","GE":"Georgia","DE":"Germany","GH":"Ghana","GI":"Gibraltar","GR":"Greece","GL":"Greenland","GD":"Grenada","GP":"Guadeloupe","GU":"Guam","GT":"Guatemala","GG":"Guernsey","GN":"Guinea","GW":"Guinea-Bissau","GY":"Guyana","HT":"Haiti","HM":"Heard Island and McDonald Islands","VA":"Holy See","HN":"Honduras","HK":"Hong Kong","HU":"Hungary","IS":"Iceland","IN":"India","ID":"Indonesia","IR":"Iran","IQ":"Iraq","IE":"Ireland","IM":"Isle of Man","IL":"Israel","IT":"Italy","JM":"Jamaica","JP":"Japan","JE":"Jersey","JO":"Jordan","KZ":"Kazakhstan","KE":"Kenya","KI":"Kiribati","KP":"Korea, Democratic People's Republic of","KR":"Korea, Republic of","KW":"Kuwait","KG":"Kyrgyzstan","LA":"Lao People's Democratic Republic","LV":"Latvia","LB":"Lebanon","LS":"Lesotho","LR":"Liberia","LY":"Libya","LI":"Liechtenstein","LT":"Lithuania","LU":"Luxembourg","MO":"Macao","MG":"Madagascar","MW":"Malawi","MY":"Malaysia","MV":"Maldives","ML":"Mali","MT":"Malta","MH":"Marshall Islands","MQ":"Martinique","MR":"Mauritania","MU":"Mauritius","YT":"Mayotte","MX":"Mexico","FM":"Micronesia","MD":"Moldova","MC":"Monaco","MN":"Mongolia","ME":"Montenegro","MS":"Montserrat","MA":"Morocco","MZ":"Mozambique","MM":"Myanmar","NA":"Namibia","NR":"Nauru","NP":"Nepal","NL":"Netherlands","NC":"New Caledonia","NZ":"New Zealand","NI":"Nicaragua","NE":"Niger","NG":"Nigeria","NU":"Niue","NF":"Norfolk Island","MK":"North Macedonia","MP":"Northern Mariana Islands","NO":"Norway","OM":"Oman","PK":"Pakistan","PW":"Palau","PS":"Palestine, State of","PA":"Panama","PG":"Papua New Guinea","PY":"Paraguay","PE":"Peru","PH":"Philippines","PN":"Pitcairn","PL":"Poland","PT":"Portugal","PR":"Puerto Rico","QA":"Qatar","RE":"R\u00e9union","RO":"Romania","RU":"Russian Federation","RW":"Rwanda","BL":"Saint Barth\u00e9lemy","SH":"Saint Helena, Ascension and Tristan da Cunha","KN":"Saint Kitts and Nevis","LC":"Saint Lucia","MF":"Saint Martin","PM":"Saint Pierre and Miquelon","VC":"Saint Vincent and the Grenadines","WS":"Samoa","SM":"San Marino","ST":"Sao Tome and Principe","SA":"Saudi Arabia","SN":"Senegal","RS":"Serbia","SC":"Seychelles","SL":"Sierra Leone","SG":"Singapore","SX":"Sint Maarten","SK":"Slovakia","SI":"Slovenia","SB":"Solomon Islands","SO":"Somalia","ZA":"South Africa","GS":"South Georgia and the South Sandwich Islands","SS":"South Sudan","ES":"Spain","LK":"Sri Lanka","SD":"Sudan","SR":"Suriname","SJ":"Svalbard and Jan Mayen","SE":"Sweden","CH":"Switzerland","SY":"Syria Arab Republic","TW":"Taiwan","TJ":"Tajikistan","TZ":"Tanzania, the United Republic of","TH":"Thailand","TL":"Timor-Leste","TG":"Togo","TK":"Tokelau","TO":"Tonga","TT":"Trinidad and Tobago","TN":"Tunisia","TR":"T\u00fcrkiye","TM":"Turkmenistan","TC":"Turks and Caicos Islands","TV":"Tuvalu","UG":"Uganda","UA":"Ukraine","AE":"United Arab Emirates","GB":"United Kingdom","US":"United States","UY":"Uruguay","UM":"US Minor Outlying Islands","UZ":"Uzbekistan","VU":"Vanuatu","VE":"Venezuela","VN":"Viet Nam","VG":"Virgin Islands, British","VI":"Virgin Islands, U.S.","WF":"Wallis and Futuna","EH":"Western Sahara","YE":"Yemen","ZM":"Zambia","ZW":"Zimbabwe"},"strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved. The content contains the link to return and complete the form."}}; //# sourceURL=gform_gravityforms-js-extra var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"bd2ea601f0155d066a4f3802a65e82de"},"ajax":{"ajaxurl":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","ajax_submission_nonce":"d21fa2eb7e","i18n":{"step_announcement":"Step %1$s of %2$s, %3$s","unknown_error":"There was an unknown error processing your request. Please try again.","error_403":"The request was blocked (403 error) for unknown security reasons. Remove any code-like text (scripts or DB queries) and try again."}}}},"hmr_dev":"","public_path":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/assets/js/dist/","config_nonce":"424d34be2f"}; //# sourceURL=gform_gravityforms_theme-js-extra {"baseUrl":"https://s.w.org/images/core/emoji/17.0.2/72x72/","ext":".png","svgUrl":"https://s.w.org/images/core/emoji/17.0.2/svg/","svgExt":".svg","source":{"concatemoji":"https://www.cardiolrx.com/wp-includes/js/wp-emoji-release.min.js?ver=7.1"}} /*! This file is auto-generated */ var e="script#wp-emoji-settings",t=document.querySelector(e);if(!(t instanceof HTMLScriptElement))throw new Error("Element missing: "+e);const r=JSON.parse(t.text),s=(window._wpemojiSettings=r,"wpEmojiSettingsSupports"),o=["flag","emoji"];function i(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(s,JSON.stringify(t))}catch(e){}}function c(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0);const r=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);return t.every((e,t)=>e===r[t])}function p(e,t){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var n=e.getImageData(16,16,1,1);for(let e=0;e<n.data.length;e++)if(0!==n.data[e])return!1;return!0}function u(e,t,n,r){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\udde8\ud83c\uddf6","\ud83c\udde8\u200b\ud83c\uddf6")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!r(e,"\ud83e\u1fac8")}return!1}function f(e,t,n,r){let a;const s=(a="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):document.createElement("canvas")).getContext("2d",{willReadFrequently:!0}),o=(s.textBaseline="top",s.font="600 32px Arial",{});return e.forEach(e=>{o[e]=t(s,e,n,r)}),o}function a(e){var t=document.createElement("script");t.src=e,t.defer=!0,document.head.appendChild(t)}r.supports={everything:!0,everythingExceptFlag:!0},new Promise(t=>{let n=function(){try{var e=JSON.parse(sessionStorage.getItem(s));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(o),u.toString(),c.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"});const a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=e=>{i(n=e.data),a.terminate(),t(n)})}catch(e){}i(n=f(o,u,c,p))}t(n)}).then(e=>{for(const n in e)r.supports[n]=e[n],r.supports.everything=r.supports.everything&&r.supports[n],"flag"!==n&&(r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&r.supports[n]);var t;r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&!r.supports.flag,r.supports.everything||((t=r.source||{}).concatemoji?a(t.concatemoji):t.wpemoji&&t.twemoji&&(a(t.twemoji),a(t.wpemoji)))}); //# sourceURL=https://www.cardiolrx.com/wp-includes/js/wp-emoji-loader.min.js gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 8) {if(typeof Placeholders != 'undefined'){ Placeholders.enable(); }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "1", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, 1 ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );

The release as fetched from its publisher. cardiolrx.com ↗